Compare AbCellera Biologics Inc (ABCL) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

XLRE trades at $44.29, down 0.9% on the day, with technical indicators showing a neutral to bearish bias. The ETF maintains a low 0.08% expense ratio and focuses exclusively on U.S. real estate investment trusts. Recent news highlights XLRE's cost advantage over global real estate ETFs and discusses the REIT sector's resilience amid interest rate volatility.

The outlook for XLRE hinges on U.S. real estate fundamentals and interest rate trends. Opportunities include potential sector recovery and durable dividends, but risks remain from rising Treasury yields and economic uncertainty. Wall Street sentiment is mixed, with technicals suggesting near-term consolidation around key support at $44.